Nektar Therapeutics Reports First Quarter 2022 Financial Results

SAN FRANCISCO, May 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2022. Cash and investments in marketable securities at March 31, 2022 were approximately $704.4 million as compared to $798.8 million at...

Click to view original post